BR112018016725A2 - composição farmacêutica para prevenir e tratar transtornos do sono - Google Patents

composição farmacêutica para prevenir e tratar transtornos do sono

Info

Publication number
BR112018016725A2
BR112018016725A2 BR112018016725A BR112018016725A BR112018016725A2 BR 112018016725 A2 BR112018016725 A2 BR 112018016725A2 BR 112018016725 A BR112018016725 A BR 112018016725A BR 112018016725 A BR112018016725 A BR 112018016725A BR 112018016725 A2 BR112018016725 A2 BR 112018016725A2
Authority
BR
Brazil
Prior art keywords
sleep disorders
pharmaceutical composition
prevent
treat sleep
relates
Prior art date
Application number
BR112018016725A
Other languages
English (en)
Portuguese (pt)
Inventor
Konstantinovich Syrov Kirill
Viktorovich Nesteruk Vladimir
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of BR112018016725A2 publication Critical patent/BR112018016725A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018016725A 2016-02-18 2017-02-16 composição farmacêutica para prevenir e tratar transtornos do sono BR112018016725A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016105535A RU2620855C1 (ru) 2016-02-18 2016-02-18 Фармацевтическая композиция для профилактики и лечения нарушений сна
PCT/RU2017/000077 WO2017142442A1 (ru) 2016-02-18 2017-02-16 Фармацевтическая композиция для профилактики и лечения нарушений сна

Publications (1)

Publication Number Publication Date
BR112018016725A2 true BR112018016725A2 (pt) 2019-04-30

Family

ID=59032329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016725A BR112018016725A2 (pt) 2016-02-18 2017-02-16 composição farmacêutica para prevenir e tratar transtornos do sono

Country Status (9)

Country Link
KR (1) KR20180101539A (ko)
CN (1) CN108697645A (ko)
BR (1) BR112018016725A2 (ko)
CL (1) CL2018002337A1 (ko)
EA (1) EA201891647A1 (ko)
HK (1) HK1255631A1 (ko)
MX (1) MX2018009921A (ko)
RU (1) RU2620855C1 (ko)
WO (1) WO2017142442A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
US9700548B2 (en) * 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
WO2014138162A1 (en) * 2013-03-05 2014-09-12 Requis Pharmaceuticals Inc. Preparations for the treatment of sleep-related respiratory disorders

Also Published As

Publication number Publication date
RU2620855C1 (ru) 2017-05-30
WO2017142442A1 (ru) 2017-08-24
HK1255631A1 (zh) 2019-08-23
MX2018009921A (es) 2018-11-09
CL2018002337A1 (es) 2018-11-30
EA201891647A1 (ru) 2018-12-28
KR20180101539A (ko) 2018-09-12
CN108697645A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
BR112018010671A2 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2019000625A1 (es) Combinación de agonistas de fxr.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2013001910A1 (es) Compuestos derivados de fenil-isoxazol; metodo para prepararlos; composicion farmaceutica que los comprende; combinacion que los comprende junto a otro agente terapeutico o preventivo de infecciones virales; metodo para prevenir o tratar infecciones virales; y su uso para el tratamiento de infecciones virales.
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
BR112018016725A2 (pt) composição farmacêutica para prevenir e tratar transtornos do sono
BR112017028025A2 (pt) complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) [chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements